The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | CAR T-cells and CRISPR: The future of AML treatment
New and invigorating methods of tackling acute myeloid leukemia (AML) are being researched at present. In this interview, Saar Gill, MD, PhD from the University of Pennsylvania, Philadelphia, PA talks about his research into AML, which focuses on CD33 and CD123 using CAR T-cell therapy. Dr Gill discusses the current issues with this therapy and provides an overview of how his group is planning to overcome these problem by utilising CRISPR-Cas9. This interview was recorded at the International Conference of Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH).
